10x Genomics improves profitability and raises annual revenue guidance
TXG 10x Genomics Inc
$62.90 -3.31%
View chart & analysis → - 110x Genomics recorded a loss per share of $0.15 in the third quarter, achieving a surprise rate of 25.0%.
- 210x Genomics reported third-quarter revenue of $150.67 million, showing a 31.8% improvement in loss compared to the previous year.
- 310x Genomics raised its annual revenue guidance from $625 million to $635 million.
So what's the key point?
10x Genomics earned more revenue than experts expected and reduced its losses. The company also raised its annual revenue target to $635 million.
Source Earnings Whispers +3 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.